Allylestrenol

Allylestrenol

Systematic (IUPAC) name
(17β)-17-(prop-2-en-1-yl)estr-4-en-17-ol
Clinical data
Pregnancy category	Used in threatened miscarriage and RPL
Identifiers
CAS Number	432-60-0
ATC code	G03DC01 (WHO)
PubChem	CID 235905
DrugBank	DB01431
ChemSpider	205855
UNII	I47VB5DZ8O
KEGG	D01374
ChEMBL	CHEMBL1445549
Synonyms	17α-Allylestr-4-en-17β-ol
Chemical data
Formula	C21H32O
Molar mass	300.48 g/mol
SMILES O[C@]2(CC[C@H]1[C@H]4[C@H](CC[C@@]12C)[C@@H]3\C(=C/CCC3)CC4)C\C=C
InChI InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1 Key:ATXHVCQZZJYMCF-XUDSTZEESA-N
(what is this?)  (verify)

Allylestrenol (BAN/INN), also known as allyloestrenol and allyl estrenol, is a synthetic progestogen used to prevent threatened miscarriage, recurrent pregnancy loss and premature labor.^[1][2] In men, it has also been studied as a treatment for benign prostatic hyperplasia, with encouraging results.^[3][4]

Allylestrenol is sold under several trade names, including Gestin, Turinal, Gestrenol, Gestanin, Gestanol or Gestanon, Maintaine, Orageston, and Profar. It is currently not marketed in the United States, United Kingdom, or Canada, but as of 2011, is extensively used in Bangladesh, Japan, Russia, India, and much of Southeast Asia.^[1]

Allylestrenol is a 19-nortestosterone derivative.^[5]

References

1. Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: the complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2082. ISBN 978-0-85369-840-1.
2. Cortés-Prieto J, Bosch AO, Rocha JA (1980). "Allylestrenol: three years of experience with Gestanon in threatened abortion and premature labor". Clinical Therapeutics 3 (3): 200–8. PMID 7459930.
3. Fukuoka H, Ishibashi Y, Shiba T, Tuchiya F, Sakanishi S (July 1993). "[Clinical study of allylestrenol (Perselin) on patients with prostatic hypertrophy]". Hinyokika Kiyo. Acta Urologica Japonica (in Japanese) 39 (7): 679–83. PMID 7689782.
4. Noguchi K, Takeda M, Hosaka M, Kubota Y (May 2002). "[Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH]". Hinyokika Kiyo. Acta Urologica Japonica (in Japanese) 48 (5): 269–73. PMID 12094708.
5. Jeffrey K. Aronson (21 February 2009). Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. pp. 289–. ISBN 978-0-08-093292-7.

External links

• "AUA 2007 - Prostate Cancer Basic Research (II)" - Uro Today